ALK and non-small cell lung carcinoma: For ALK+ NSCLC, lorlatinib is a novel, highly potent, brain-penetrant, third-generation ALK TKI with broad-spectrum potency against most known resistance mutations that can develop during treatment with existing first- and second-generation ALK TKIs; its efficacy is significant in BM and LM (29).